CSF proteomics identifies early changes in autosomal dominant Alzheimer’s diseaseYuanyuan Shen, Muhammad Ali, Ciyang Wang et al.|Cell|2024Cited by 60
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Yan Li et al.|The Lancet Neurology|2025Cited by 39
α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burdenJohannes Levin, Simone Baiardi, Corinne Quadalti et al.|Alzheimer s & Dementia|2024Cited by 37